US2023250071A1PendingUtilityA1
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
Est. expiryJan 24, 2034(~7.5 yrs left)· nominal 20-yr term from priority
Inventors:Hans Roland LonnStephen ConnollySteven SwallowStaffan Po KarlssonCarl-Johan AurellJohn Fritiof PonténKevin James DoyleAmanda Jane Van De PoëlGraham Peter JonesDavid Wyn WatsonJaqueline Anne MacritchieNicholas John Palmer
C07D 267/10C07D 413/14A61K 31/553A61K 45/06C07D 413/12C07D 417/12A61P 11/00A61P 11/06A61P 11/08A61P 11/14A61P 31/06A61P 31/12A61P 31/16A61P 35/00A61P 37/08A61P 43/00
87
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof),that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
Claims
exact text as granted — not AI-modified1 . A compound of formula (I)
or a pharmaceutically-acceptable salt thereof,
wherein
R 1 is
X is selected from O, S or CF 2 ;
Y is selected from O or S;
Q is selected from CH or N;
R 6 is selected from C 1-3 alkyl, OH, OC 1-3 alkyl, N(C 1-3 alkyl) 2 , cyclopropyl, or tetrahydropyran, wherein the C 1-3 alkyl is optionally substituted by 1, 2 or 3 F;
R 7 is selected from hydrogen, F, Cl or CH 3 ; and wherein the compound of Formula (I) is further substituted with R 6 .
2 . The compound according to claim 1 wherein
R 1 is
or a pharmaceutically acceptable salt thereof.
3 . The compound according to claim 2 wherein
X is O;
R 7 is hydrogen.
4 . The compound according to claim 1 , wherein R 6 is independently selected from C 1-3 alkyl and OC 1-3 alkyl.
5 . The compound according to claim 1 , wherein R 6 is independently selected from CH 3 and OCH 3 .
6 . A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.
7 . A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 2 and a pharmaceutically acceptable adjuvant, diluent or carrier.
8 . A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 3 and a pharmaceutically acceptable adjuvant, diluent or carrier.
9 . A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 4 and a pharmaceutically acceptable adjuvant, diluent or carrier.
10 . A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 5 and a pharmaceutically acceptable adjuvant, diluent or carrier.
11 . A method of treating an obstructive disease of the airway in a patient suffering from said disease, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 .
12 . A method of treating an obstructive disease of the airway in a patient suffering from said disease, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as claimed in claim 2 .
13 . A method of treating an obstructive disease of the airway in a patient suffering from said disease, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as claimed in claim 3 .
14 . A method of treating an obstructive disease of the airway in a patient suffering from said disease, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as claimed in claim 4 .
15 . A method of treating an obstructive disease of the airway in a patient suffering from said disease, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) as claimed in claim 5 .
16 . The method of claim 11 , wherein the obstructive disease of the airway is bronchiectasis, cystic fibrosis, asthma, or chronic obstructive pulmonary disease (COPD).
17 . The method of claim 16 , wherein the obstructive disease of the airway is bronchiectasis.
18 . The method of claim 16 , wherein the obstructive disease of the airway is cystic fibrosis.
19 . The method of claim 12 , wherein the obstructive disease of the airway is bronchiectasis, cystic fibrosis, asthma, or chronic obstructive pulmonary disease (COPD).
20 . The method of claim 19 , wherein the obstructive disease of the airway is bronchiectasis.
21 . The method of claim 19 , wherein the obstructive disease of the airway is cystic fibrosis.
22 . The method of claim 13 , wherein the obstructive disease of the airway is bronchiectasis, cystic fibrosis, asthma, or chronic obstructive pulmonary disease (COPD).
23 . The method of claim 22 , wherein the obstructive disease of the airway is bronchiectasis.
24 . The method of claim 22 , wherein the obstructive disease of the airway is cystic fibrosis.
25 . The method of claim 14 , wherein the obstructive disease of the airway is bronchiectasis, cystic fibrosis, asthma, or chronic obstructive pulmonary disease (COPD).
26 . The method of claim 25 , wherein the obstructive disease of the airway is bronchiectasis.
27 . The method of claim 25 , wherein the obstructive disease of the airway is cystic fibrosis.
28 . The method of claim 15 , wherein the obstructive disease of the airway is bronchiectasis, cystic fibrosis, asthma, or chronic obstructive pulmonary disease (COPD).
29 . The method of claim 28 , wherein the obstructive disease of the airway is bronchiectasis.
30 . The method of claim 28 , wherein the obstructive disease of the airway is cystic fibrosis.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.